News
FDA Suspends U.S. License of Chikungunya Vaccine
By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports of serious side effects in older adults similar to the symptoms of chikungunya virus.
FDA suspends license for chikungunya vaccine Ixchiq over serious safety concerns
The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker Valneva's chikungunya vaccine, saying that continued administration of the vaccine to the public would pose a danger to health.
The U.S. Food and Drug Administration (USFDA) has suspended the biologics license of Ixchiq (Chikungunya Vaccine, Live), ...
Hong Kong saw two new imported cases of chikungunya fever on Tuesday, bringing the total to 11 so far this year. One ...
The Level III emergency response to the Chikungunya outbreak in Foshan, Guangdong province, was terminated on Tuesday, as the ...
Mosquito-borne chikungunya virus has caused an outbreak in China, but public health experts say the risk for spread and ...
Health agencies recommend wearing insect repellent and loose-fitting clothing to prevent bites from mosquitoes carrying the ...
The cities of Foshan and Guangzhou, in southern China, have been battling the virus for two months. Nearly 10,000 cases have ...
DEAR DR. ROACH: I have a friend who lives in Paraguay and had been diagnosed with chikungunya. It has been extremely painful ...
Dear J.: Chikungunya may not sound like a real medical condition, but it is a viral disease that was first found in West ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback